In this instance you are right. Let me tell you ab

In this instance you are right. Let me tell you about a company I once followed many years back that reminds me of the early stages AMBS. Sounds familiar, right? The company is called Targacept. The company focuses on Neuronal Nicotinic Receptors (NNR)and was spun out by big tobacci due to their exceptional research on NNRs. NNRs looked to have a bright future in treating many different diseases that include memory, attention, mood, uro-genital function, pain, inflammation, movement, and cell survival. With a boat load of cash and many "small molecule" candidates/trials, the company went to try and prove how NNR can be manipulated to cure people. Things looked really promising at the get go. Fast forward to today. The company is a shell of itself with none of their trials panning out and only one "small molecule" program left. They burned through 100s of millions of dollars and had to drastically scale back their operation to cut costs, not unlike any biotech with failed trials. Of course, the stock suffered. NNRs might actually prove to have medical use but TRGT has yet to figure it out yet with their stable of "small molecules."

My point is that until MANF actually shows it works in a clinical setting with real humans, all of this research crap that Watsonfaker and the other partisans on here pump mean absolutely nothing. All it is is "interesting" research data.

The market seems to agree too.

My Agenda: To see Amarantus prosper so I can make a nice return on my investment.